This is a Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation, Single Center Bridging Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects.

Key Inclusion Criteria:

• Healthy male and female volunteers aged 18-55 years.
• 19kg/m2 ≤ BMI <24kg/m2.

Key Exclusion Criteria:

• A positive HBsAg, HCV Ab and/or HIV Ab.
• Pancreatic injury or pancreatitis.
• History of organ transplantation, including bone marrow transplantation.